Could Local Surgery Improve Survival in Stage IV Breast Cancer? | ||
| SECI Oncology Journal | ||
| Volume 11, Issue 4, October 2023, Pages 339-351 | ||
| Abstract | ||
| Background: Metastatic breast cancer (Stage IV) accounts for 3% of all newly diagnosed patients with breast cancer in Japan, which is not different from that of USA (6%) reported according to the Surveillance, Epidemiology and End Results data. The treatment of Stage IV breast cancer has traditionally been palliative care with chemotherapy, hormonal therapy and/or radiation therapy. Young patients with limited metastatic (oligometastatic) disease and an excellent performance status tend to be long-term survivors. Combined treatment for such patients including surgery, provide better chance for longterm progression-free survival than systemic therapy alone. Objective: Evaluating overall survival and progression free survival for metastatic breast cancer patients underwent mastectomy plus systemic therapy versus that on systemic therapy alone. Patients and methods: This randomized study was conducted in surgical oncology department, medical oncology department, South Egypt Cancer Institute, Assiut University. We prospectively review and compare women presented with metastatic breast cancer between from January 2014 and December 2020, who received primary tumor resection (group A) and women treated non-operatively (group B). Results: This study was conducted in surgical oncology department, medical oncology department -South Egypt Cancer Institute, Assiut University. we retrospectively and prospectively review and compare women (200 patients) presented with metastatic breast cancer between January 2014 and December 2019, who received surgery to the breast and women treated non-operatively. The study includes 67 patients who underwent surgery (42 patients underwent primary surgery then systemic treatment the others 25 patients received 1ry systemic treatment then underwent surgery) and 133 patients received only systemic treatment. Overall survival and progression free survival was 63.0% and 58.5% respectively, mean time of OS was28.1100 ± 1.3012 with range of 6 – 60 months and mean time of PFS was 26.0700 ± 1.3110 with range of 5 – 57 months. Conclusion: Historically the standard treatment for metastatic breast cancer was systemic therapy and surgical resection of primary tumor was specified for palliation but with advanced understanding of tumor microbiology and animal module studies extent of surgery in advanced breast cancer increases. | ||
| Keywords | ||
| Metastatic breast cancer; Stage IV breast cancer; Overall Survival; Progression Free Survival and Surgical and non-surgical | ||
|
Supplementary Files
|
||
|
Statistics Article View: 37 |
||
